International Stem Cell (International Stem Cell) Interest Coverage : 0 (At Loss) (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. International Stem Cell's Operating Income for the three months ended in Mar. 2024 was $-0.18 Mil. International Stem Cell's Interest Expense for the three months ended in Mar. 2024 was $-0.04 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for International Stem Cell's Interest Coverage or its related term are showing as below:

ISCO's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 152.38
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

International Stem Cell Interest Coverage Historical Data

The historical data trend for International Stem Cell's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

International Stem Cell Interest Coverage Chart

International Stem Cell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

International Stem Cell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial															0.06	-	-	-	-

Competitive Comparison of International Stem Cell's Interest Coverage

For the Biotechnology subindustry, International Stem Cell's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

International Stem Cell's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Interest Coverage distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Interest Coverage falls into.

International Stem Cell Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

International Stem Cell's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, International Stem Cell's Interest Expense was $-0.14 Mil. Its Operating Income was $-0.66 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.45 Mil.

International Stem Cell did not have earnings to cover the interest expense.

International Stem Cell's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, International Stem Cell's Interest Expense was $-0.04 Mil. Its Operating Income was $-0.18 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.37 Mil.

International Stem Cell did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

International Stem Cell (OTCPK:ISCO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

International Stem Cell Interest Coverage Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

International Stem Cell (International Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website

https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

Executives

Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin	10 percent owner	1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova	officer: Dir. of Legal Affairs & Oper.	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don	director	2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens	officer: Acting Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi	officer: Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin	director, 10 percent owner	2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak	officer: Interim CFO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw	officer: Executive Vice President	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund	director	C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc	10 percent owner	5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May	officer: President and COO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen	officer: Chief Financial Officer	5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus	director, officer: President	2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027